Viking Therapeutics stock debate

What happened: Shares of Viking Therapeutics (NASDAQ: VKTX) surged in June, driven by optimism around its lead candidate, VK2735, a dual formulation weight-loss therapy. Analysts anticipate positive Phase 3 trial results in the coming years, with one projecting an 188% upside. Viking's pipeline includes several promising obesity treatments, with the global market expected to reach $150 billion by 2035.

Market impact: The biotechnology sector, particularly obesity drug developers, is affected. Viking's success could challenge established players like Eli Lilly and Novo Nordisk, potentially reshaping the competitive landscape. Investors are closely watching Viking's clinical trials, as positive results could drive further stock price appreciation.

What to watch next: Key catalysts include the completion of Phase 3 trials for VK2735, expected in 2024-2025. Additionally, regulatory decisions on VK2735's approval will significantly influence Viking's future. Lastly, watch for updates on Viking's other pipeline candidates, as progress could further boost investor confidence.